1. Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat. Issue 1 (2nd January 2018) Authors: Gautam, Ashish; Zhu, Yanyan; Ma, Esprit; Lee, Shih-Yuan; Zagadailov, Erin; Teasell, Jeremy; Richhariya, Akshara; Bonthapally, Vijayveer; Huebner, Dirk Journal: Leukemia & lymphoma Issue: Volume 59:Issue 1(2018) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Issue 10094 (5th August 2017) Authors: Prince, H Miles; Kim, Youn H; Horwitz, Steven M; Dummer, Reinhard; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Sanches, Jose A; Ortiz-Romero, Pablo L; Akilov, Oleg E; Geskin, Larisa; Trotman, Judith; Taylor, Kerry; Dalle, Stephane; Weichenthal, Michael; Walewski, Ja... Journal: Lancet Issue: Volume 390:Issue 10094(2017) Page Start: 555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting. (February 2015) Authors: Seal, Brian; Sullivan, Sean D; Ramsey, Scott; Asche, Carl V; Shermock, Kenneth M; Sarma, Syam; Zagadailov, Erin; Farrelly, Eileen; Eaddy, Michael Journal: Future oncology Issue: Volume 11:Number 3(2015) Page Start: 439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial. Issue 10 (October 2022) Authors: Glenthøj, Andreas; van Beers, Eduard J; Al-Samkari, Hanny; Viprakasit, Vip; Kuo, Kevin H M; Galactéros, Frédéric; Chonat, Satheesh; Porter, John; Zagadailov, Erin; Xu, Rengyi; Oluyadi, Abdulafeez; Hawkins, Peter; Gheuens, Sarah; Beynon, Vanessa; Barcellini, Wilma Journal: Lancet Issue: Volume 9:Issue 10(2022) Page Start: e724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. (21st September 2018) Authors: Bröckelmann, Paul J.; McMullen, Suzanne; Wilson, J Ben; Mueller, Kerstin; Goring, Sarah; Stamatoullas, Aspasia; Zagadailov, Erin; Gautam, Ashish; Huebner, Dirk; Dalal, Mehul; Illidge, Tim Journal: British journal of haematology Issue: Volume 184:Number 2(2019) Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. (July 2020) Authors: Dummer, Reinhard; Prince, Henry M.; Whittaker, Sean; Horwitz, Steven M.; Kim, Youn H.; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Eradat, Herbert; Pinter-Brown, Lauren; Sanches, Jose A.; Ortiz-Romero, Pablo L.; Akilov, Oleg E.; Geskin, Larisa; Huen, Auris; Walewski... Journal: European journal of cancer Issue: Volume 133(2020) Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review. Issue 4 (2nd April 2020) Authors: Dalal, Mehul; Mitchell, Stephen; McCloskey, Conor; Zagadailov, Erin; Gautam, Ashish Journal: Expert review of hematology Issue: Volume 13:Issue 4(2020) Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗